Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

The JAK2 Inhibitor Fedratinib Inhibits Thiamine Uptake - A Putative Mechanism for the Onset of Wernicke's Encephalopathy.

Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, Rupar M, Behshad E, Gardiner C, Collier P, Liu P, Burn T, Wynn R, Hollis G, Yeleswaram S.

Drug Metab Dispos. 2014 Jul 25. pii: dmd.114.058883. [Epub ahead of print]

PMID:
25063672
[PubMed - as supplied by publisher]
2.

The Pharmacokinetics, Pharmacodynamics and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers.

Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2014 Jun 26. doi: 10.1002/jcph.354. [Epub ahead of print]

PMID:
24965573
[PubMed - as supplied by publisher]
3.

Increasing pediatric resident simulated resuscitation performance: A standardized simulation-based curriculum.

Stone K, Reid J, Caglar D, Christensen A, Strelitz B, Zhou L, Quan L.

Resuscitation. 2014 Aug;85(8):1099-105. doi: 10.1016/j.resuscitation.2014.05.005. Epub 2014 May 12.

PMID:
24830871
[PubMed - in process]
4.

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.

Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF.

J Immunother Cancer. 2014 Feb 18;2:3. doi: 10.1186/2051-1426-2-3. eCollection 2014.

PMID:
24829760
[PubMed]
Free PMC Article
5.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S.

Int J Gen Med. 2014 Jan 29;7:89-101. doi: 10.2147/IJGM.S51800. eCollection 2014.

PMID:
24501543
[PubMed]
Free PMC Article
6.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.

PMID:
24368888
[PubMed]
Free PMC Article
7.
8.

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC.

Genet Test Mol Biomarkers. 2013 May;17(5):429-37. doi: 10.1089/gtmb.2012.0366. Epub 2013 Mar 28.

PMID:
23537216
[PubMed - indexed for MEDLINE]
9.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Vaddi K, Sarlis NJ, Gupta V.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Review.

PMID:
23051187
[PubMed - indexed for MEDLINE]
10.

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.

Vaddi K, Luchi M.

Expert Opin Investig Drugs. 2012 Jul;21(7):961-73. doi: 10.1517/13543784.2012.690029. Epub 2012 May 22. Review.

PMID:
22612502
[PubMed - indexed for MEDLINE]
11.

The interplay between inhibition of JAK2 and HSP90.

Fridman JS, Sarlis NJ.

JAKSTAT. 2012 Apr 1;1(2):77-9. doi: 10.4161/jkst.20293.

PMID:
24058754
[PubMed]
Free PMC Article
12.

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A.

J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24.

PMID:
22281165
[PubMed - indexed for MEDLINE]
13.

INCB38579, a novel and potent histamine Hâ‚„ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions.

Shin N, Covington M, Bian D, Zhuo J, Bowman K, Li Y, Soloviev M, Qian DQ, Feldman P, Leffet L, He X, He Wang K, Krug K, Bell D, Czerniak P, Hu Z, Zhao H, Zhang J, Yeleswaram S, Yao W, Newton R, Scherle P.

Eur J Pharmacol. 2012 Jan 30;675(1-3):47-56. doi: 10.1016/j.ejphar.2011.11.027. Epub 2011 Nov 27.

PMID:
22155710
[PubMed - indexed for MEDLINE]
14.

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K, Kong L, Glenn J, Anand R, Meloni D, Robinson DJ, Shao L, Storace L, Li M, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Metcalf B.

ACS Med Chem Lett. 2011 Oct 5;2(12):913-8. doi: 10.1021/ml200199c. eCollection 2011 Dec 8.

PMID:
24900280
[PubMed]
Free PMC Article
15.

Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.

Haley PJ.

Toxicol Pathol. 2012;40(2):261-6. doi: 10.1177/0192623311427569. Epub 2011 Nov 14. Review.

PMID:
22083586
[PubMed - indexed for MEDLINE]
Free Article
16.

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA.

Clin Cancer Res. 2011 Nov 15;17(22):7127-38. doi: 10.1158/1078-0432.CCR-11-1157. Epub 2011 Sep 14.

PMID:
21918175
[PubMed - indexed for MEDLINE]
Free Article
17.

Development of c-MET pathway inhibitors.

Liu X, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2011 Sep;20(9):1225-41. doi: 10.1517/13543784.2011.600687. Epub 2011 Jul 11. Review.

PMID:
21740293
[PubMed - indexed for MEDLINE]
18.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K.

J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.

PMID:
21677670
[PubMed - indexed for MEDLINE]
Free Article
19.

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.

Xue CB, Feng H, Cao G, Huang T, Glenn J, Anand R, Meloni D, Zhang K, Kong L, Wang A, Zhang Y, Zheng C, Xia M, Chen L, Tanaka H, Han Q, Robinson DJ, Modi D, Storace L, Shao L, Sharief V, Li M, Galya LG, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B.

ACS Med Chem Lett. 2011 Mar 31;2(6):450-4. doi: 10.1021/ml200030q. eCollection 2011 Jun 9.

PMID:
24900329
[PubMed]
Free PMC Article
20.

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20.

PMID:
21602517
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk